AUTHORS
Yuting Yan, MD, Weihao Chen2, Tingyu of Wang3, Wenjie Xiong4, Tengteng Yu, MD5, Weiwei Sui6, Ying Yu7, Zhen Yu, MD8, Wei LIU9, Wenyang Huang, MD10, Yan Xu, MD11, Liang Huang, MD12, Dehui Zou, MD13, Gang An, MD14, Lu-Gui Qiu, PhD15, Shuhua Yi, DO16
AFFILIATIONS
1 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
13 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
14 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
15 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
16 National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Introduction: Relapse after anti-CD19 chimeric antigen receptor (CAR) T-cell therapy remains an unmet need in relapsed or refractory (R/R) B-cell lymphoma. CD20×CD3 bispecific antibodies may control disease before infusion and provide complementary CD20-directed immune pressure afterward, but prospective data on planned peri-CAR T-cell integration are lacking.
Methods: This phase Ib/II trial (NCT06464185) enrolled adults with R/R B-cell lymphoma after ≥2 anti-CD20-containing regimens. After leukapheresis, patients received obinutuzumab followed by 3 cycles of glofitamab-based induction, lymphodepletion, anti-CD19 CAR T cells (2×10^6 CAR-positive cells/kg), and up to 3 glofitamab maintenance cycles from ≥1 month after infusion. Additional induction agents were permitted for rapidly progressive disease. Maintenance doses of 5, 10, and 30 mg were evaluated using a 3+3 design. Endpoints included safety, feasibility, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), response, duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Results: At the July 2026 data cutoff, 53 patients were enrolled; 51 (96%) successfully underwent CAR T-cell infusion and 47/51 (92%) initiated maintenance. Among infused patients, median age was 54 years (range, 31–79), 84% had stage III/IV disease, the median number of prior lines was 3 (range, 2–8), 65% were refractory to their last therapy, and 58% had TP53 alterations. Diagnoses were DLBCL not otherwise specified (NOS; 47%), transformed indolent lymphoma (33%), Richter transformation (10%), mantle cell lymphoma (6%), and follicular lymphoma (4%). No DLTs or maintenance dose reductions occurred; the MTD was not reached, and 30 mg was selected as the RP2D.
Cytokine release syndrome (CRS) occurred in 27/53 patients (51%; grade ≥3, 4%) during induction, 20/51 (39%; all grade 1–2) after CAR T-cell infusion, and 3/47 (6%; all grade 1–2) during maintenance. No immune effector cell-associated neurotoxicity syndrome (ICANS) occurred during induction; 1 patient had grade 1 ICANS after infusion. Grade ≥3 adverse events occurred in 36%, 96%, and 23% across the 3 stages, respectively, with post-infusion events predominantly cytopenias. Among maintenance-treated patients, hypogammaglobulinemia occurred in 40% (grade 3, 6%).
The objective response rate (ORR)/complete response rate (CRR) was 76%/57% after induction and 88%/78% 1 month after CAR T-cell infusion; the best ORR/CRR was 88%/82%. At a median follow-up of 18.6 months, 39/51 patients (76%) remained in response, including 37 (73%) in CR. Estimated 1-year DOR, PFS, and OS were 86.6% (95% CI, 77.2–97.2), 76.3% (65.4–89.0), and 81.9% (71.9–93.4), respectively. Sensitivity analyses in all 53 enrolled patients yielded 1-year PFS and OS of 73.4% and 78.8%. Despite an 80% best CRR, patients with Richter transformation had inferior OS versus those with DLBCL NOS (P=0.040). Concurrent TP53 alteration and CDKN2A deletion was associated with inferior PFS (P=0.014) and OS (P=0.009).
Median CAR T-cell Cmax and AUC 0-28d were lower in patients with a PFS event within 12 months (P=0.047 and P=0.037, respectively). Before glofitamab, the favorable-prognosis group had higher median CD3+ T-cell (P=0.027), CD8+ T-cell (P=0.022), and natural killer (NK)-cell counts (P=0.014). From pre-glofitamab to pre-lymphodepletion, NK-cell count and proportion increased by 71% and 55%, activated CD8+ T-cell proportion increased by 93%, and total, activated, and memory regulatory T-cell proportions decreased by 27%, 38%, and 32%, respectively (all q<0.05). Absolute CD3+, CD4+, and CD8+ T-cell counts did not change significantly during induction.
Conclusions: The planned sequence of glofitamab induction, anti-CD19 CAR T-cell therapy, and glofitamab maintenance was feasible; the CRR increased across treatment stages, responses were durable, and no apparent accumulation of acute immune toxicity was observed. Before CAR T-cell infusion, glofitamab induction shifted peripheral immunity toward a less regulatory, more cytotoxic profile without significantly reducing absolute T-cell counts. Whether and how this remodeling supports subsequent CAR T-cell activity requires validation by single-cell profiling and mass cytometry.
DISCLOSURES
Yuting Yan, MD: No relevant conflicts of interest to declare.